Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is MindMaze Therapeutics Holding Cash-to-Debt?
MindMaze Therapeutics HoldingXSWX:MMTX +3.33%4 Cash-to-Debt is 5.25 as of Dec. 2025, which is at its 10-year median of 5.25. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 1,397 Biotechnology companies, MindMaze Therapeutics Holding ranks worse than 52.97% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MindMaze Therapeutics Holding's cash to debt ratio for the quarter that ended in Dec. 2025 was 5.25.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MindMaze Therapeutics Holdingcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for MindMaze Therapeutics Holding's Cash-to-Debt or its related term are showing as below:
XSWX:MMTX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 5.25 Med: 5.25 Max: 5.25
Current: 5.25
During the past 2 years, MindMaze Therapeutics Holding's highest Cash to Debt Ratio was 5.25. The lowest was 5.25. And the median was 5.25.
XSWX:MMTX's Cash-to-Debt is ranked worse than 52.97% of 1397
companies
in the Biotechnology industry
Industry Median: 6.78
vs XSWX:MMTX: 5.25
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
MindMaze Therapeutics Holding Cash-to-Debt Related Terms
MindMaze Therapeutics Holding Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MindMaze Therapeutics Holding Cash-to-Debt Chart
MindMaze Therapeutics Holding Annual Data
Trend
Dec24
Dec25
Cash-to-Debt
N/A
5.25
MindMaze Therapeutics Holding Semi-Annual Data
Dec24
Dec25
Cash-to-Debt
N/A
5.25
XSWX:MMTX vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding (XSWX:MMTX) has a Cash-to-Debt of 5.25 as of Dec. 2025. This is near median its historical median of 5.25. Over the past decade, MindMaze Therapeutics Holding's Cash-to-Debt has ranged from 5.25 to 5.25. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #740 out of 1397 companies in the Biotechnology industry, placing it in the top 53%.
Is MindMaze Therapeutics Holding's Cash-to-Debt too high?
MindMaze Therapeutics Holding's current Cash-to-Debt of 5.25 is near median its 10-year median of 5.25. Over the past 10 years, this metric has ranged from a low of 5.25 to a high of 5.25. The Biotechnology industry median Cash-to-Debt is 6.78. MindMaze Therapeutics Holding's value of 5.25 is 22.6% below this industry median. Based on the distribution chart, MindMaze Therapeutics Holding ranks #740 out of 1397 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #740 out of 1397 companies for Cash-to-Debt. This places MindMaze Therapeutics Holding in the lower half of its industry. The industry median Cash-to-Debt is 6.78. MindMaze Therapeutics Holding's value of 5.25 is 22.6% below this benchmark. Historically, MindMaze Therapeutics Holding's own Cash-to-Debt has ranged from 5.25 to 5.25 over the past decade. While the company's 10-year median is 5.25 vs. the industry median of 6.78, MindMaze Therapeutics Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindMaze Therapeutics Holding's current Cash-to-Debt of 5.25 is 22.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current Cash-to-Debt is 5.25, which is near median its own 10-year median of 5.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Cash-to-Debt of 5.25. The current Cash-to-Debt is 5.25, which is near median its 10-year median of 5.25 and 22.6% below the Biotechnology industry median of 6.78. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Cash-to-Debt is 5.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
